NFATc4‑RSK2 phospho‑switch controls calcineurin/NFAT attenuation and sarcopenia

Hypothesis

NFATc4 functions as a calcium‑sensitive brake on calcineurin‑driven atrophy signaling. In young muscle, RSK2‑mediated phosphorylation of NFATc4 promotes its nuclear import and stabilizes a repressive complex with HDAC3 that keeps the atrogin‑1 and MuRF1 promoters silent. With age, declining RSK2 activity (or increased phosphatase activity) reduces NFATc4 phosphorylation, shifting the equilibrium toward a de‑phosphorylated state that has lower DNA affinity and fails to recruit HDAC3. Consequently, calcineurin/NFAT signaling is no longer restrained, leading to miR‑23a loss and activation of the ubiquitin‑proteasome atrophy program. This model explains why NFATc4 knockout mice show no overt phenotype (the brake is already released in young tissue) yet predicts that restoring NFATc4 phosphorylation in aged muscle will attenuate atrophy independently of nerve activity.

Novel mechanistic reasoning

1. Phospho‑dependent co‑repressor recruitment – We propose that phosphorylated NFATc4 creates a docking site for HDAC3 via a phospho‑serine‑binding pocket, a interaction not described for other NFAT isoforms. De‑phosphorylation abolishes this contact, converting NFATc4 from a repressor to a neutral or weakly activating factor.
2. Fiber‑type specific RSK2 expression – RSK2 is enriched in fast‑twitch fibers; thus, the NFATc4 brake is stronger in tibialis anterior than soleus, matching the observed fiber‑type differences in NFATc1 nuclear localization and providing a built‑in susceptibility to atrophy in fast muscles during aging.
3. Feedback with miR‑23a – Loss of miR‑23a not only derepresses atrogin‑1/MuRF1 but also reduces RSK2 translation (miR‑23a predicts RSK2 3′‑UTR binding), creating a double‑negative loop that accelerates the transition from brake‑on to brake‑off.

Testable predictions

• Prediction 1: In 24‑month‑old mice, soleus and tibialis anterior will show decreased phospho‑NFATc4 (Ser‑xxx) levels compared with 3‑month‑old controls, while total NFATc4 remains unchanged.
• Prediction 2: Muscle‑specific overexpression of a phospho‑mimetic NFATc4 (S→D) in aged mice will preserve HDAC3‑NFATc4 co‑immunoprecipitation, maintain miR‑23a expression, and reduce atrogin‑1/MuRF1 mRNA by ≥40% relative to GFP controls.
• Prediction 3: Knock‑down of RSK2 in young adult tibialis anterior will phenocopy the aged state: reduced phospho‑NFATc4, loss of HDAC3 interaction, increased nuclear NFATc4 signal (due to impaired export), and elevated atrophy markers despite normal calcineurin activity.
• Prediction 4: Treating aged mice with a selective RSK2 activator (e.g., FKBP12‑rapamycin‑derived small molecule) will restore NFATc4 phosphorylation, enhance HDAC3 recruitment, and improve grip strength and fiber cross‑sectional area by ≥25% over vehicle.

Experimental approach

1. Western blot & phospho‑specific antibodies for NFATc4 in microdissected soleus and TA from young vs. old mice.
2. Co‑immunoprecipitation of NFATc4 with HDAC3 under basal and RSK2‑modulated conditions.
3. AAV‑mediated gene delivery of phospho‑mimetic or phospho‑dead NFATc4 constructs, followed by qPCR for miR‑23a, atrogin‑1, MuRF1, and MyHC isoforms.
4. Functional assays: in‑vivo grip strength, treadmill endurance, and histologic fiber‑type analysis.
5. Pharmacological rescue using an RSK2 activator, with appropriate vehicle and inhibitor controls.

If the data confirm that phosphorylated NFATc4 sustains a repressive HDAC3 complex that limits atrophy signaling, the hypothesis will be validated. Conversely, if phospho‑mimetic NFATc4 fails to rescue miR‑23a or atrophy markers, or if RSK2 manipulation does not alter NFATc4‑HDAC3 interaction, the model will be falsified, prompting a reassessment of NFATc4’s role in muscle aging.